Skip to main content
OpenTrials
Completed

NCT Number: NCT06152094

UCSF BP Activate Letter Study

The BP Activate Study aims to assess the effectiveness of the BP Report letter with personalized BP medication recommendations, compared with Control letters and no intervention, at shortening time to appointment, time to visit, time to medication change, and time to achievement of BP goal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

About this study

The BP Activate Study is a randomized quality improvement trial. We will deliver one of two versions of a letter to established English-speaking primary care patients at Mt Zion with uncontrolled hypertension, defined by SBP>140 or DBP>90 in the past two years (identified via EHR). The letter will prompt patients to schedule a visit with their provider or team nurse practitioner to discuss their BP recommendations with their clinician. We will test 2 versions of the letter and a usual care control:

  • The "BP Activate Report Letter" group will get a letter that presents recommendations for medication changes from a computerized algorithm using the patient's medical records and recommends discussing these specific recommendations with their clinician; or
  • The "Control Letter" group will get a letter that suggests they talk to their clinician about their BP without providing any specific medication recommendations.
  • The "Usual Care" group will not receive any intervention.

This primary goal of the study is to assess the effectiveness of the BP Activate Report Letter compared with the Control Letter, and see if it shortens time to appointment, time to visit, time to medication change (primary outcome), and time to achievement of BP goal. Clinicians, with patient input, will still have full control of how BP is clinically managed. A small number of patients will be contacted by a research coordinator to hear what they thought when they received the letter, and why they did or did not act upon the information.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is a primary care patient of a clinician in a general internal medicine clinic who has agreed to have their patients participate in the study
  • Lowest SBP>140 or lowest DBP>90 at last visit in general internal medicine clinic
  • Last visit in general internal medicine clinic was < 2 years ago
  • EngageRx algorithm determines that a medication intensification step is indicated

Exclusion criteria

  • Primary language is not English
  • Patient's provider indicates (through an active opt-out process) that they do not want the patient to receive a BP Activate letter

Treatment and study plan

BP Activate Letter

Other

Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and "computer-generated medication recommendations that might improve your blood pressure", along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.

Control Letter

Other

Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.

Primary outcomes

  1. Time to medication change or demonstrated BP control at 6 months

    Time frame: 6 months

    Time is measured as number of days between randomization date and the day that a participant is prescribed a new anti-HTN medication or an increase in dose of a prior anti-HTN medication, or they have a documented BP measurement <140 mmHg systolic and <90 mmHg diastolic.

Secondary outcomes

  1. Time to medication change or demonstrated BP control at 3 months

    Time frame: 3 months

    Time is measured as number of days between randomization date and the day that a participant is prescribed a new anti-HTN medication or an increase in dose of a prior anti-HTN medication, or they have a documented BP measurement <140 mmHg systolic and <90 mmHg diastolic.

  2. Time to completed visit at 3 months

    Time frame: 3 months

    Time to medication change is defined as number of days between randomization and the day the participant completes a visit in the Division of General Internal Medicine.

  3. Time to BP goal at 3 months

    Time frame: 3 months

    Time is defined as number of days from randomization until first documentation of a BP measurement <140 mmHg systolic and <90 mmHg diastolic.

  4. Time to medication change at 3 months

    Time frame: 3 months

    Time is measured as number of days between randomization date and the day that a participant is prescribed a new anti-HTN medication or an increase in dose of a prior anti-HTN medication.

  5. Time to completed visit at 6 months

    Time frame: 6 months

    Time to medication change is defined as number of days between randomization and the day the participant completes a visit in the Division of General Internal Medicine.

  6. Time to BP goal at 6 months

    Time frame: 6 months

    Time is defined as number of days from randomization until first documentation of a BP measurement <140 mmHg systolic and <90 mmHg diastolic.

  7. Time to medication change at 6 months

    Time frame: 6 months

    Time is measured as number of days between randomization date and the day that a participant is prescribed a new anti-HTN medication or an increase in dose of a prior anti-HTN medication.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

UCSF BP Activate Letter Randomized Clinical Trial

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Nov 30, 2023
Registry last updated
Jan 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.